Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Updates from the ADVANCE study

Francesco Maura • 22 Aug 2022
IMS 2022
Multiple Myeloma Antibodies Carfilzomib Daratumumab Dexamethasone Lenalidomide
ADVANCE

Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, shares some updates from the ADVANCE study (NCT03290950), which is comparing the combination of daratumumab, carfilzomib, lenalidomide, and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed myeloma. This study is also evaluating measurable residual disease (MRD) negativity as the primary endpoint. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

More from Francesco Maura

SMM & MGUS: clinical relevance, the PROMISE study & the role of genomics
Elizabeth O'Donnell et al. • 25 Mar 2024
3:43
Genomic profiling to predict prognosis for patients with HR-SMM
Francesco Maura • 8 Dec 2023
1:15
Using genomic alterations to predict relapse following immunotherapy in multiple myeloma
Francesco Maura • 8 Dec 2023
2:08
Novel genomic alterations driving tumor suppressor gene inactivation in multiple myeloma
Francesco Maura • 8 Dec 2023

Related Videos

0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
The content of VJHemOnc is intended for healthcare professionals